United States · Platforms & data · The Motley Fool

Novo Nordisk (NVO) Q3 2026 Earnings Call Transcript

Published by The Motley Fool · United States 1 h ago

Wegovy pill uptake and CagriSema trial results shape the growth recovery story.

Read the full article on The Motley Fool Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.fool.com)

Also worth reading

Ralliant Corporation Non-GAAP EPS of $0.93, revenue of $620M

These stocks have soared the most today after the Democrats trounced Trump

Stryker (NYSE:SYK) Price Target Cut to $336.00 by Analysts at Rothschild & Co Redburn

Eversource Energy earnings on deck after Q2 miss, estimate cuts

10-year Treasury yield slides as traders mull over Democrats' midterm victories, oil prices drop

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030